Changes in Metabolic Parameters and Determination of Minimal Clinically Important Difference in YGTSS-TTS Using Data From the Randomized Phase 2b and Open-Label Extension Studies of Ecopipam For Tourette Syndrome (P11-6.002)
To determine if ecopipam increases metabolic syndrome risk and define the minimal clinically important difference (MCID) in YGTSS-TTS in children/adolescents with Tourette syndrome (TS) who completed a phase 2b randomized controlled trial (RCT) and 12-month open-label extension (OLE) study.
Authors
- Richard M. Bittman
- Donald L. Gilbert (ORCID: https://orcid.org/0000-0002-9245-6878)
- Jennifer L. McGuire (ORCID: https://orcid.org/0000-0002-8245-7199)
- George B. Karkanias (ORCID: https://orcid.org/0009-0006-3510-5816)
- Timothy Cunniff
- Sarah D. Atkinson (ORCID: https://orcid.org/0000-0002-3208-8794)
- Stephen P. Wanaski
- Frederick E. Munschauer
- Gage D. Messner
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Paragon Genomics (United States) (US)
- University of Cincinnati (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211256
- Primary Topic
- Obsessive-Compulsive Spectrum Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00